Nexalin Technology shares surge 14.44% premarket as expanding peer-reviewed DIFS research confirms leadership in non-invasive brain stimulation.

Nexalin Technology surged 14.44% in premarket trading following the announcement that its expanding peer-reviewed neuroimaging research confirms the efficacy of its DIFS™ technology in non-invasive brain stimulation. The study, published two days prior, highlighted improved attention and normalized brain activity in ADHD patients, reinforcing the company’s scientific validation and therapeutic potential. This recent development aligns with Nexalin’s ongoing clinical advancements, including prior FDA Q-submissions and regulatory approvals, which collectively strengthen investor confidence in its Alzheimer’s and ADHD treatment pipelines. The premarket rally reflects renewed optimism about the company’s research milestones and market positioning in the neurostimulation sector.